With the vast majority of BC cases having HR+ disease, and ER+ or PR+ disease continuing to be the most common type of BC diagnosed [1], it is likely that hormonal–based therapy will remain the mainstay of BC treatment moving forward, including the treatment of HR+/HER-2 positive subtypes in early and advanced stages of BC [6, 7]. The gene discussed is ERBB2; the disease is breast cancer.